Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wisconsin ginseng

This article was originally published in The Tan Sheet

Executive Summary

Wisconsin Democrats Sen. Russ Feingold and Rep. David Obey introduced companion bills to protect U.S. ginseng producers and consumers on April 20 and 21, respectively. The Ginseng Harvest Labeling Act (S 854 and HR 1740) "would require that ginseng, as a raw agricultural commodity, be sold at retail with a label clearly indicating the country that the ginseng was harvested in," according to a statement from Feingold's office. The legislation is a defensive measure against smugglers from Canada and Asia who have been falsely labeling their product as "Wisconsin grown"...

You may also be interested in...



Wisconsin Delegation Proposes “Country Of Harvest” On Raw Ginseng Labels

Members of the congressional delegation from Wisconsin, where about 95 percent of U.S. ginseng is cultivated, have proposed amending agricultural manufacturing regulations to require labels for raw ginseng roots indicate the country of harvest

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel